Spero Therapeutics Announces Positive Topline Results from its PSPRO: Spero Therapeutics, Inc.
2020-09-08 07:30:10
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
